文献速递临床试验与 GCP流行病学与生物统计

FiO2-C 试验的统计分析计划:闭环自动控制吸入氧浓度对极早产儿结局的影响——一项安全性及有效性的随机对照平行组多中心试验

Statistical analysis plan for the FiO2-C trial: effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcomes of extremely preterm infants-a randomized-controlled parallel group multicentre trial for safety and efficacy.
PubMed 文献 · Trials · 2024-11-12

FiO2-C 试验是一项设盲结局评估、多中心、随机对照平行组优效性试验,研究在常规手动控制(RMC)基础上加用闭环自动控制吸入氧浓度(FiO2-C)对极早产儿(胎龄小于28周)短期和长期临床结局的影响。设定两个共同主要复合结局:①死亡、严重早产儿视网膜病变(ROP)、支气管肺发育不良(BPD)或坏死性小肠结肠炎(NEC),评估至矫正胎龄36周或ROP视网膜完全血管化;②死亡或神经发育障碍(NDI),评估至矫正年龄2岁。主要结局采用Cochran-Mantel-Haenszel检验比较,按随机化因素(中心、性别、出生胎龄<26周和≥26周)分层,结果以校正比值比及双侧95%和97.5%置信区间和双侧P值呈现。

要点

  • FiO2-C 在常规手动控制基础上可能减少极早产儿低氧和高氧血症发作,但对ROP、BPD、NEC、NDI和死亡的影响尚未研究。
  • 两个共同主要复合结局分别在矫正胎龄36周(或ROP视网膜完全血管化时)和矫正年龄2岁评估。
  • 主要分析采用Cochran-Mantel-Haenszel检验,按中心、性别和出生胎龄(<26周和≥26周)分层,报告校正比值比及双侧95%和97.5%置信区间。

核心结论

  • 本统计分析计划在任意统计分析之前发布,详细规定了FiO2-C试验的统计分析,符合赫尔辛基宣言和国际人用药品注册技术协调会药物临床试验质量管理规范指南。

研究设计与样本

  • 多中心、随机对照、平行组优效性试验,采用结局评估者设盲设计,比较在常规手动控制(RMC)基础上加用闭环自动控制吸入氧浓度(FiO2-C,由标准婴儿呼吸机提供)与仅RMC对极早产儿(胎龄小于28周)短期和长期临床结局的影响。

主要发现

  • 原文未报告结果。

关键数值与推荐

  • 共同主要复合结局一:死亡、严重早产儿视网膜病变(ROP)、支气管肺发育不良(BPD)或坏死性小肠结肠炎(NEC),评估至矫正胎龄36周,ROP评估至视网膜完全血管化。
  • 共同主要复合结局二:死亡或神经发育障碍(NDI,定义为语言/认知迟缓、运动障碍、严重视觉损害或听力损害),评估至矫正年龄2岁。
  • 主要结局采用Cochran-Mantel-Haenszel检验比较,按随机化因素(中心、性别和出生胎龄<26周和≥26周)分层,结果以校正比值比及双侧95%和97.5%置信区间和双侧P值呈现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extremely low gestational age neonates (ELGANs, i.e. those born before 28 weeks postmenstrual age (PMA)) often require supplemental oxygen and frequently experience intermittent hypo- and hyperoxemic episodes. Exposure to episodes with inadequate oxygen concentrations has been shown to be associated with an increased risk of retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), neurodevelopmental impairment (NDI) and death. Closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) reduces number and duration of hypo- and hyperoxemic episodes in ELGANs. Its impacts on clinically important short- and long-term outcomes such as ROP, BPD, NEC, NDI and mortality have not yet been studied. METHODS: An outcome-assessor-blinded, multicentre, randomized-controlled, parallel-group trial for superiority was designed to study the effects of FiO2-C (provided by standard infant ventilators) in addition to routine manual control (RMC) during respiratory support, compared to RMC only, on short- and long-term clinical outcomes in ELGANs. Two co-primary composite outcomes were defined: (i) death, severe ROP, BPD or NEC, assessed at 36 weeks PMA or, in case of ROP, until complete vascularization of the retina; (ii) death or NDI (defined as language/cognitive delay, motor impairment, severe visual impairment or hearing impairment), assessed at 2 years corrected age. RESULTS: Primary outcomes will be compared between the two intervention groups using a Cochran-Mantel-Haenszel test. The factors considered for randomization (centre, sex and gestational age at birth (< 26 weeks and ≥ 26 weeks)) will be used to define strata. Results will be presented as adjusted odds ratios with two-sided 95% and 97.5% confidence intervals and two-sided p values. CONCLUSIONS: The statistical analyses for the FiO2-C trial were defined in the study protocol and specified in detail in this statistical analysis plan published prior to any statistical analysis. This is in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. TRIAL REGISTRATION: ClinicalTrials.gov NCT03168516. Registered on May 30, 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. König J, Stauch A, Engel C, et al. Statistical analysis plan for the FiO2-C trial: effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcomes of extremely preterm infants-a randomized-controlled parallel group multicentre trial for safety and efficacy. Trials. 2024. PMID: 39533330. doi:10.1186/s13063-024-08615-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。